New hope for kidney cancer patients when first treatment fails
NCT ID NCT07460206
Summary
This study is for people with advanced clear-cell kidney cancer that has come back after they received a specific immunotherapy drug (pembrolizumab) as a preventative treatment after surgery. It aims to see if combining that same immunotherapy with a different drug (lenvatinib) can help control the cancer. The trial will enroll about 108 participants to measure how well the combination works and how safe it is for this specific group of patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CCRCC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.